OBJECTIVE: At present, the differences in the efficacy between PET/CT and MRI for the detection of bone metastases in patients with cancer have not been clearly delineated. We performed a meta-analysis to compare the performance of FDG PET/CT with that of gadolinium-enhanced MRI for the detection of bone metastases in patients with cancer. METHODS: Studies about PET/CT and MRI for the detection of bone metastases were systematically searched in the MEDLINE, EMBASE, and EBM Review databases. We calculated sensitivities, specificities, diagnostic odds ratios, positive likelihood ratios, negative likelihood ratios (NLR), and constructed summary receiver operating characteristic curves using bivariate regression models for PET/CT and MRI, respectively. RESULTS: Across 9 studies (1116 patients), FDG PET/CT has similar patient-based sensitivity (0.803 vs 0.837), specificity (0.989 vs 0.977), diagnostic odds ratio (309.0 vs 221.9), positive likelihood ratio (61.7 vs 37.0), and negative likelihood ratio (0.200 vs 0.167) with gadolinium-enhanced MRI. Areas under the curve with 95% confidence interval for FDG PET/CT and gadolinium-enhanced MRI were 0.99 (0.98-0.99) and 0.98 (0.97-0.99), respectively. CONCLUSIONS: FDG PET/CT and gadolinium-enhanced MRI have excellent diagnostic performance for the detection of bone metastases in patients with cancer.
OBJECTIVE: At present, the differences in the efficacy between PET/CT and MRI for the detection of bone metastases in patients with cancer have not been clearly delineated. We performed a meta-analysis to compare the performance of FDG PET/CT with that of gadolinium-enhanced MRI for the detection of bone metastases in patients with cancer. METHODS: Studies about PET/CT and MRI for the detection of bone metastases were systematically searched in the MEDLINE, EMBASE, and EBM Review databases. We calculated sensitivities, specificities, diagnostic odds ratios, positive likelihood ratios, negative likelihood ratios (NLR), and constructed summary receiver operating characteristic curves using bivariate regression models for PET/CT and MRI, respectively. RESULTS: Across 9 studies (1116 patients), FDG PET/CT has similar patient-based sensitivity (0.803 vs 0.837), specificity (0.989 vs 0.977), diagnostic odds ratio (309.0 vs 221.9), positive likelihood ratio (61.7 vs 37.0), and negative likelihood ratio (0.200 vs 0.167) with gadolinium-enhanced MRI. Areas under the curve with 95% confidence interval for FDG PET/CT and gadolinium-enhanced MRI were 0.99 (0.98-0.99) and 0.98 (0.97-0.99), respectively. CONCLUSIONS: FDG PET/CT and gadolinium-enhanced MRI have excellent diagnostic performance for the detection of bone metastases in patients with cancer.
Authors: Stuart A Taylor; Susan Mallett; Anne Miles; Stephen Morris; Laura Quinn; Caroline S Clarke; Sandy Beare; John Bridgewater; Vicky Goh; Sam Janes; Dow-Mu Koh; Alison Morton; Neal Navani; Alfred Oliver; Anwar Padhani; Shonit Punwani; Andrea Rockall; Steve Halligan Journal: Health Technol Assess Date: 2019-12 Impact factor: 4.014
Authors: Stuart A Taylor; Sue Mallett; Sandy Beare; Gauraang Bhatnagar; Dominic Blunt; Peter Boavida; John Bridgewater; Caroline S Clarke; Marian Duggan; Steve Ellis; Robert Glynne-Jones; Vicky Goh; Ashley M Groves; Ayshea Hameeduddin; Sam M Janes; Edward W Johnston; Dow-Mu Koh; Anne Miles; Stephen Morris; Alison Morton; Neal Navani; John O'Donohue; Alfred Oliver; Anwar R Padhani; Helen Pardoe; Uday Patel; Shonit Punwani; Laura Quinn; Hameed Rafiee; Krystyna Reczko; Andrea G Rockall; Khawaja Shahabuddin; Harbir S Sidhu; Jonathan Teague; Mohamed A Thaha; Matthew Train; Katherine van Ree; Sanjaya Wijeyekoon; Steve Halligan Journal: Lancet Gastroenterol Hepatol Date: 2019-05-09
Authors: Stuart A Taylor; Sue Mallett; Simon Ball; Sandy Beare; Gauraang Bhatnagar; Angshu Bhowmik; Peter Boavida; John Bridgewater; Caroline S Clarke; Marian Duggan; Steve Ellis; Robert Glynne-Jones; Vicky Goh; Ashley M Groves; Ayshea Hameeduddin; Sam M Janes; Edward W Johnston; Dow-Mu Koh; Sara Lock; Anne Miles; Stephen Morris; Alison Morton; Neal Navani; Alfred Oliver; Terry O'Shaughnessy; Anwar R Padhani; David Prezzi; Shonit Punwani; Laura Quinn; Hameed Rafiee; Krystyna Reczko; Andrea G Rockall; Peter Russell; Harbir S Sidhu; Nicola Strickland; Kathryn Tarver; Jonathan Teague; Steve Halligan Journal: Lancet Respir Med Date: 2019-05-09 Impact factor: 30.700